Beacon

The Elegance of Evolution

Why the most effective cancer immunotherapy should start with a microbe

Why the most effective cancer immunotherapy should start with a microbe

Why the most effective cancer immunotherapy should start with a microbe

Nothing energizes the innate immune system better, or more durably, than a microbial infection. Immunotherapies for cancer depend on activating and expanding a dormant immune system. The immune system cannot afford to ignore microbial infections, so it evolved robust and durable activation and expansion pathways in response to bacteria. Laguna’s strategy is guided by that evolution. In an evolution-guided immunotherapy, every step, from how the therapy enters the body to how the immune system responds, uses pathways the immune system already optimized through millions of years of evolution, and no cell or system is forced to work against its evolved function. The most effective immunotherapy should therefore start with a microbe, and Laguna starts with the microbial pathogen, Listeria monocytogenes.

Safely Mimic an Infection

To generate an effective immunotherapy from a microbial pathogen, you must first make the microbe safe. Listeria is dangerous because it has developed many tools for escaping and evading the immune system. In the blood and other extracellular spaces, Listeria is vulnerable and can easily be killed by neutrophils. Immediately after an infection, most Listeria is in fact eaten by phagocytic cells such as macrophages and dendritic cells. This would be the end of the infection for most other microbes, because they would be killed inside the phago-lysosome, but for Listeria it’s only the beginning. Within the phago-lysosome, Listeria activates a pore-forming toxin called listeriolysin O that allows it to easily escape into the cytosol, where it can feed and rapidly grow (doubling about once an hour), then spread from cell to cell via actin tails that look like microscopic rocket engines. To make Listeria safe, and generate QUAIL, we used precision genome engineering to remove the pathogenic genes that make it possible for Listeria to survive outside of cells, and to spread from cell to cell. The resulting organism is inert outside of cells and cannot spread. In addition to removing its ability to cause infection, we have also solved a key challenge of living therapies. Because QUAIL cannot grow, divide, persist, or survive, the dose we administer is consistent, reliable, and has minimal variation within a patient.

Once inside a cell, Listeria never needs to expose itself to the vulnerable extracellular environment ever again because they can penetrate cell membranes and spread from cell to cell. As a result, antibodies are close to irrelevant, and the only way to beat Listeria is to find and kill infected cells. Each of these actions, escaping the phago-lysosome (TLR2 & NLRP3), growing within the cytosol (HMBPP, NOD1/2, cGAS & STING), and spreading from cell to cell via actin tails (DAMPs) sets off a specific alarm, and this combination of alarms mobilizes a massive innate immune response that starts with γδ T cells. Once eaten by a phagocytic immune cell, QUAIL can still escape the phago-lysosome and grow in the cytosol, releasing HMBPP and setting off the alarms that durably activate and robustly expand γδ T cells. However, QUAIL cannot ever escape the immune cells that consumed it. Unable to spread and cause infection, it will die, and no QUAIL will survive within a patient for more than 2 days after a dose. The activated and expanded γδ T cells will persist for weeks to months, diligently searching for cancer cells.

The elegance of an evolution-guided approach is that every part of the system is operating exactly as millions of years of evolution has optimized it to operate. Innate immune cells consume Listeria; Listeria escapes into the cytosol of innate immune cells; innate alarms awaken an otherwise dormant population of γδ T cells. Our engineering does not require any system to work against its evolved function, it simply pushes the microbe to enter cells it already wants to enter, then traps it within its captor.

Kill the Correct Cells

To generate an effective immunotherapy from a microbial pathogen, the activated and expanded immune cells must then search for and kill cancer cells, not “infected” cells. Innate γδ T cells have T cell receptors and kill through perforins, granzymes, and cytokine release, but they do not recognize a target the way adaptive T cells do. They respond to chemical and stress signals that reveal a cell is infected or transformed, even when that cell displays no foreign antigen. Instead of searching for protein antigens, γδ T cells search for “phosphoantigens” such as HMBPP that are produced in large concentrations by intracellular Listeria and signal to γδ T cells through extracellular receptors (BTN3A1 & BTN2A1, which change shape upon intracellular phosphoantigen binding to signal to γδ T cells). The pathway within QUAIL that produces HMBPP is essential for survival therefore γδ T cells have evolved to sense a signal that the bacteria cannot lose. Coincidentally, when a cell “transforms” from a healthy cell to a cancer cell, it necessarily produces phosphoantigens making it look like an infected cell. And like the microbe, the cancer cell cannot stop producing phosphoantigen, it is a necessary byproduct of becoming more metabolically active. However, only expressing phosphoantigens is not enough to be killed by a γδ T cell.

They require phosphoantigen expression, and a combination of other signals on target cells, and this is why they may be ideal immune cells for distinguishing cancer from healthy tissue. Through the act of growing quickly, cancer cells display other signals that identify them as pathogenic. They may lose the ability to display antigen (loss of MHC-1), and they may signal DNA damage or intracellular stress from excess protein production through extracellular proteins (Fas & MICA/B). Loss of antigen display is how cancer cells escape adaptive T cells, antibodies, and CAR-T cells, and it is also one of the signals that marks them for γδ T cells. Individual cancer cells may not express all these signals, but any unregulated, rapidly growing and dividing cancer cell will express some combination of these signals. These will be recognized, targeted, and killed by the circulating γδ T cells that have been activated by QUAIL. A cancer cell cannot hide the metabolism and stress of rapid growth.

The elegance of this evolution-guided approach is evident in that every part of our strategy operates exactly as it has been optimized over millions of years of evolution. The mechanisms that enable cancer cells to evade adaptive T cells, and engineered CAR-T and antibody therapies are the exact mechanisms that leave cancer cells specifically and uniquely vulnerable to γδ T cells. The signals that mark cells transformed by infection and unlock γδ T cell recognition and killing are mirrored on cells transformed by cancer. Our immunotherapy does not require any system to work against its evolved function, it simply pushes the γδ T cells down an activation cascade that leads to killing cancer cells.

Durable Long-Lasting Protection

To generate an effective immunotherapy from a microbial pathogen, the activated and expanded immune cells must be durable. Using Listeria to activate and expand endogenous γδ T cells has the advantage that durability can be achieved both through the physiology of γδ T cells and their role in the innate immune system, and because Listeria can be dosed repeatedly without loss of efficacy. Because QUAIL will not survive within a patient for more than 2 days after a dose, each dose is a self-limited infection. In previous clinical studies evaluating attenuated Listeria, patients rarely developed a memory T cell or an antibody response against the microbe supporting that QUAIL can be dosed repeatedly. These results are further supported by studies in nonhuman primates where repeated exposure to Listeria produced larger and faster γδ T cell expansions. The alarms that drive the innate T cell response are produced every time, giving reason to expect that each dose will build upon the last, generating a sustained, long-term immune response to eliminate tumors.

Activating an immune response through innate T cells initiates a cascade that results in evolutionarily optimized, durable protection. Activated γδ T cells do far more than kill their targets, they become the centerpiece of an orchestrated, comprehensive, long-term immune response. Upon activation, they release cytokines (IFN-γ & TNF-α) that arm macrophages, help dendritic cells mature, and help prime adaptive T cells to generate long-term memory. After killing a target cell, the antigens released from that cell can be collected by dendritic cells that received maturation signals from the γδ T cells. These dendritic cells will then train and prime memory T and B cells that were also activated by the initial γδ T cell response. This produces new antibodies and energizes immune cells against the unique and specific signals from the patient’s tumor. This is a complete immune response. Innate alarms lead to innate T cells, innate T cells educate the adaptive immune system, and the adaptive immune system makes coordinated and precise attacks that are stored as memory to prevent a tumor from recurring.

The elegance of this evolution-guided approach is evident in that every part of our strategy operates exactly as it has been optimized over millions of years of evolution. QUAIL activates γδ T cells, which orchestrate a comprehensive immune response. Our immunotherapy does not require any part of the immune system to work against its evolved function, it simply mimics the first step of an infection and lets every immune cell and interaction pathway in our bodies finish the response that leads to long-lasting protection.

Challenges of Existing Immunotherapies

Existing immunotherapies are not evolution-guided, because they take the opposite path. They are built upon the adaptive and memory immune system, without the necessary innate immune activation that ensures a robust and durable response. Charles Janeway called the fact that antigen alone does not produce a T cell response the immunologist’s dirty little secret. The innate system supplies the context that turns a T cell that has merely seen an antigen into one that commits, expands, and produces memory, and each of the approaches below lacks the innate immune system.

  • Checkpoint inhibitors push against evolutionarily optimized pathways by turning off the brakes to force an adaptive T cell to be active for longer than it was designed to be. This strategy has not worked in “cold” tumors, where T cells are absent or inactive because they were never primed by dendritic cells and other innate immune cells. PD-1 and CTLA-4 evolved as brakes because chronic activation damages tissue and because T cells that are stimulated without end become exhausted, and the colitis, pneumonitis, myocarditis, and endocrine toxicities seen in patients are the predictable price of releasing them.

  • CAR-T cells have been engineered with a specific target and a synthetic co-stimulatory signal and will not be activated and trained by dendritic cells. By starting with the final product, scientists and engineers produced something that will perfectly kill one target, but may quickly become exhausted, and will be ineffective if that target mutates. The CAR also replaces the finely tuned signaling of a T cell receptor reading peptide on MHC with an engineered receptor that binds a surface protein, often one also found on healthy tissue, and its signaling domains can fire even when no antigen is present. Cytokine release syndrome, neurotoxicity, the need for lymphodepleting chemotherapy, and a manufacturing process built around one patient at a time all follow from that design.

  • In vivo CAR-T strategies aim to avoid the complexity and cost of manufacturing traditional CAR-T therapies by moving the T cell genetic engineering inside of the patient, which keeps all of the risk and complexity of that engineering and gives up the controls of a manufacturing facility. It’s important to note that every natural defense of our cells, including the formation of a nucleus has evolved to prevent changes to our genome. The strategy of in vivo CAR-T is in fact fighting against every level of defense that has evolved since the formation of eukaryotic life. Lipid particles and viral vectors are cleared by the liver and spleen and tagged by complement, foreign nucleic acid is detected by innate immune receptors (TLR3, TLR7, TLR8, RIG-I, and cGAS) as evidence of infection and their genetic engineering tools are destroyed. Some of these obstacles may be solved with creative engineering, but each solution has to overcome a defense that evolved specifically to stop it.

  • Antibodies and T cell engagers bind a target and increase the probability of killing specific cancer cells, but they cannot durably activate or robustly expand endogenous immune cells. Too often, cancer patients have depleted immune cells and cannot benefit from antibody therapies unless their immune cells can first be expanded. In patients who do have a robust immune system, the targets of these antibodies can also exist on healthy cells, which leads to serious toxicities. Alternatively, cancer cells can evolve to lose the targets, leaving the immune cells looking for a signal that is no longer there. Repeated administration of these antibodies makes matters worse, because it can exhaust T cells and deplete healthy immune cells, leaving patients with a diminished immune system to fight against relapse and recurrence and more vulnerable to opportunistic infections.

While each of these approaches has led to clinical breakthroughs and changed the lives of patients, most of them do not invigorate the immune system in ways that will lead to durable, long-lasting cures, and the reasons are built into their design. Each starts at the end of the immune response and works against an evolved safeguard, which produces predictable failure modes, including toxicity when immune cells are pushed beyond their design or aimed at targets on healthy tissue, exhaustion when cells are stimulated without end, escape when cancer cells lose the single target, and dependence on patients who still have enough healthy immune cells to respond. We believe that the comprehensive immune response activated by QUAIL can also supplement and improve the efficacy of the immunotherapies described here. A microbial therapy can drive an innate T cell response against specific diseases, and it can raise the activation state and drive expansion of the entire immune system, which will extend the efficacy of checkpoint inhibitors, T cell engagers, and CAR-T cells into new and broader indications.

QUAIL is Optimized by Evolution

Laguna’s strategy is guided by evolution at every step. QUAIL is made safe by removing the genes that let Listeria survive outside of cells and spread from cell to cell. Once inside, it still sets off the alarms that activate and expand γδ T cells. Those γδ T cells detect the phosphoantigens and stress signals that cancer cells cannot stop producing, and after killing cancer cells they educate the adaptive immune system to build memory against the tumor. Nothing energizes the innate immune system better, or more durably, than a microbial infection, and QUAIL harnesses that response without the infection. The elegance of evolution is that it already optimized the response over millions of years. An evolution-guided strategy benefits from that optimization, while any therapy that works against evolution requires a lot more engineering, a lot more cost, and a lot more luck.

Jonathan Kotula, PhD
Jonathan Kotula, PhD

CEO and Co-Founder, Laguna Bio

CEO and Co-Founder, Laguna Bio

Jonathan Kotula is a leader in the development of next-generation living therapeutics, bringing experience across biotechnology, translational research, and clinical development.

Jonathan Kotula is a leader in the development of next-generation living therapeutics, bringing experience across biotechnology, translational research, and clinical development.

Copyright © 2026 Laguna Biotherapeutics Inc.  

All rights reserved.